Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study

Abstract

ObjectivesTo better understand the real-world impact of biologic therapy in persons with Crohn’s disease (CD) and ulcerative colitis (UC), we evaluated the effect of marketplace introduction of infliximab on the population rates of hospitalisations and surgeries and public payer drug costs.DesignWe used health administrative data to study adult persons with CD and UC living in Ontario, Canada between 1995 and 2012. We used an interrupted time series design with segmented regression analysis to evaluate the impact of infliximab introduction on the rates of IBD-related hospitalisations, intestinal resections and public payer drug costs over 10 years among patients with CD and 5 years among patients with UC, allowing for a 1-year transition.ResultsRelative to what would have been expected in the absence of infliximab, marketplace introduction of infliximab did not produce significant declines in the rates of CD-related hospitalisations (OR at the last observation quarter 1.06, 95% CI 0.811 to 1.39) or intestinal resections (OR 1.10, 95% CI 0.810 to 1.50), or in the rates of UC-related hospitalisations (OR 1.22, 95% CI 1.07 to 1.39) or colectomies (OR 0.933, 95% CI 0.54 to 1.61). The findings were similar among infliximab users, except that hospitalisation rates declined substantially among UC patients following marketplace introduction of infliximab (OR 0.515, 95% CI 0.342 to 0.777). There was a threefold rise over expected trends in public payer drug cost among patients with CD following infliximab introduction (OR 2.98,95% CI 2.29 to 3.86), suggesting robust market penetration in this group, but no significant change among patients with UC (OR 1.06, 95% CI 0.955 to 1.18).ConclusionsMarketplace introduction of infliximab has not yielded anticipated reductions in the population rates of IBD-related hospitalisations or intestinal resections, despite robust market penetration among patients with CD. Misguided use of infliximab in CD patients and underuse of infliximab in UC patients may largely explain our study findings.

The effects of proactive therapeutic drug monitoring vs reactive therapeutic drug monitoring in a virtual biologic clinic, a retrospective cohort study

“…Of those six, five patients had been recently started on IFX, and therefore, we suggest that their need for surgery was most likely as a result of the severity of underlying disease rather than loss of response to IFX. We know from previous studies that a relatively high percentage of IBD patient's will require surgery despite treatment with biologic therapy …”

Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases

“…For example, anti-TNF agents rapidly suppress inflammation and induce remission but did not change the long-term course in certain subsets of pediatric CD patients [108]. Murthy et al showed that anti-TNF therapy did not reduce the frequency of hospitalization and surgical treatments in CD patients [109]. Therefore, more physiological approaches to induce and sustain remissions with limited toxicity and high cost-effectiveness are needed.…”

Epithelial cell biomarkers are predictive of response to biologic agents in Crohn’s disease

“…6,7 IBD is a heterogeneous group of diseases with highly variable disease phenotypes and clinical courses, and patients will likely have different responses to each biologic class depending on their specific disease subtype. Despite widespread clinical adoption of anti-TNF therapy, nearly half of the CD patients placed on biologics do not experience clinical response, resulting in dramatic increase in healthcare costs without significant improvement in outcomes 8,9 The annual costs of IBD treatment have increased by 30% within the last 5 years, 9 and IBD-related hospitalizations quadrupled from 1998 to 2015. 10,11 Over the past decade, advances in disease pathogenesis from genomics, proteomics, and microbial and host metabolomic studies, also known as "multi-omics" approaches have identified key factors responsible for ongoing mucosal inflammation in IBD.…”